atl1102 ph11a & 11b, page-2

Nooooo..... I'm not far off filling my .009 order.... I shouldn't be greedy I guess. Got plenty at .010 and .011 in recent times. Was wondering when we'd hear more on 1102. Was just hoping it'd be longer before news so we continued to fly under the radar for a while. $1.5mil market and compared to the competitor it's showing a safer profile, likely to be cheaper and easier to administer. Results in just over 6 mths. Now is the time to enter for the run up in anticipation. And that's just for 1102..... journal articles land in the right hands normally for switched on investors.... nice.

“I am very pleased with the progress of our ATL1102 toxicology study and that the results of the
study remain on track for reporting early next year. I’m also delighted that our ATL1102 Phase
IIa clinical trial results are to be submitted for publication. I thank Professor Limmroth for his
support and efforts in this important initiative.
Having the data published in a peer reviewed scientific journal will be a great aid for our future
development and partnering plans.”